Compile Data Set for Download or QSAR
Report error Found 222 Enz. Inhib. hit(s) with all data for entry = 9356
TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459432BDBM459432(US10759813, Example 23-4)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459433BDBM459433(US10759813, Example 23-8)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459430BDBM459430(US10759813, Example 23-2)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459431BDBM459431(US10759813, Example 23-3)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459428BDBM459428((2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459429BDBM459429(US10759813, Example 23-1)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459426BDBM459426(US10759813, Example 21-1)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459427BDBM459427(US10759813, Example 21-2)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459424BDBM459424(US10759813, Example 20-8)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459422BDBM459422(US10759813, Example 20-6)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459423BDBM459423(US10759813, Example 20-7)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459420BDBM459420(US10759813, Example 20-4)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459421BDBM459421(US10759813, Example 20-5)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459418BDBM459418(US10759813, Example 20-2)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459419BDBM459419(US10759813, Example 20-3)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459437BDBM459437(US10759813, Example 25-3)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459434BDBM459434(5-[(S)-2-Biphenyl-4-yl-1-((R)-2-carboxy-2-hydroxy-...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459224BDBM459224(US10759813, Example 7-B)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459225BDBM459225(US10759813, Example 8-B)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459222BDBM459222(US10759813, Example 5-B)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459223BDBM459223(US10759813, Example 6-B)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459219BDBM459219(US10759813, Example 3-C | US10759813, Example 3-D)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459221BDBM459221(US10759813, Example 4-B)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459218BDBM459218(US10759813, Example 2-D)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459216BDBM459216(US10759813, Example 1-B)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459217BDBM459217(US10759813, Example 2-C)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459228BDBM459228(US10759813, Example 10-3)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459257BDBM459257(US10759813, Example 12-11)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459255BDBM459255(US10759813, Example 12-9)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459253BDBM459253(US10759813, Example 12-7)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459254BDBM459254(US10759813, Example 12-8)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459251BDBM459251(US10759813, Example 12-5)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459252BDBM459252(US10759813, Example 12-6)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459250BDBM459250(US10759813, Example 12-4)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459245BDBM459245(US10759813, Example 11-13)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459273BDBM459273(US10759813, Example 12-27)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459267BDBM459267(US10759813, Example 12-21)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459268BDBM459268(US10759813, Example 12-22)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459262BDBM459262(US10759813, Example 12-16)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459259BDBM459259(US10759813, Example 12-13)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459285BDBM459285(US10759813, Example 15-5)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459305BDBM459305(US10759813, Example 15-26)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459306BDBM459306(US10759813, Example 15-27)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459304BDBM459304(US10759813, Example 15-25)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459300BDBM459300(US10759813, Example 15-21)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459321BDBM459321(US10759813, Example 15-46)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459322BDBM459322(US10759813, Example 15-48)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459319BDBM459319(US10759813, Example 15-42)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459313BDBM459313(US10759813, Example 15-35)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandChemical structure of BindingDB Monomer ID 459311BDBM459311(US10759813, Example 15-33)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
US Patent

Displayed 1 to 50 (of 222 total ) | Next | Last >>
Jump to: